We would love to hear your thoughts about our site and services, please take our survey here.
Considering the company has £30m cash and burns about £6 per year. I think they will be able to deliver in the next 5 years considering approval delay was said to be max 12 months … I would recommend you read the annual results before your next post!
Not sure what you’re reading but considering the company was only aiming for £23m this year and £25m in 2022, but has already achieved its 2022 forecast in 2021, I’d say that announcement is pretty informative. Going from £0 forecasts 2016, 2017, 2018 to outperforming at £25m in 2021 is astounding…. It does not surprise me that they just raised £36m in very difficult market conditions for everyone else…
GE Covid backlog should be clearing now which means ScanNav assist AI’s sales (only £200k at the moment) will start to reflect global rollout under GE Healthcare. ScanNav is rolled out as a package in all new (once it clears old stock) ultrasound machines GE sells. GE healthcare has $18bn revenue (out of GE’s total revenue of $70bn). The company said that it expects AI revenue to accelerate in 2022 and that is obvious in context of GE. Sales and marketing has been up to GE so far but that also means IUG doesn’t have to pay for sales and marketing to GE’s gigantic customer base ..
https://www.bbc.co.uk/news/health-60154398
Never seen an AIM company come up on Facebook feed with 70,000 likes on BBC news page and BBC consistently reports on Polarean’s Oxford study.
When the data is published and peer reviewed I would hope for more orders from research bodies - institutions can still order the equipment on the Investigational New Drug license. The fact that the FDA didn’t rescind sale/use of the polarisers suggests the Response Letter isn’t as bad as we understood. It’s being used on children in Cincinnati and the FDA is fine with that
Good luck with that… this co has technology enhancement services for the lithium-ion and sulphur battery markets, to challenge Huawei, which are merely supporting revenue. Primary goal is putting the first and only stabilised by gel zinc battery onto the 70bn zinc battery market…. At 150m market cap…. With all of its peers trading at 1bn market cap…
I wasn’t expecting anything different from the RNS… the product launched only a few weeks ago - and with 66% efficacy in a disorder that impacts millions with no cure and many people willing to try anything that might help. I have faith in the efficacy and in CEO Stuart as a salesman.. today is just profit taking in very ugly market conditions. Skinbio is being punished for its good performance this year if anything …
Don’t forget chairman J Allis who just sold Blue Earth to Bracco for 450m. Pretty sure he knows what he’s doing in terms of radiology. Pretty sure Oxford know what they’re doing as well - https://oxfordbrc.nihr.ac.uk/research-themes-overview/imaging/sub-theme-hyperpolarised-xenon-imaging-hpx/
Because they were devastated. If you trade on the language of an RNS and not the underlying fundamentals of a business (support from Bracco (billion $ MRI company), manufactured by a huge conglomerate, been in hospitals for 4 years and has its own xenon research centre at Oxford. The language of the RNS really pales in comparison imo.. there is not safety issue. The company got badly burned by missing the mark on technicalities. They were embarrassed in that RNS - not despondent.
This isn’t a mining company or one that should trade on technicals like that. Imaging having a kid with cystic fibrosis and Polx technology tells you about it years before any other MRI/doctor opinion picks it up. Or you have fibroids after covid and you catch them so early that your life isn’t ruined. That’s what you’re investing in here - not on after hours prints… come on.
I get it - technicals. But this isn’t a mining company. This is a company that helps little kids get diagnosed with cystic fibrosis early so they can breathe better for the rest of their lives. There is much more supporting this case than looking at after hours prints. Oxford university has posted videos using the equipment to help COPD and Sheffield uses it to find damage from covid that was otherwise missed - https://www.sheffield.ac.uk/news/hidden-damage-lungs-covid-19-revealed-new-study-university-sheffield
All of this made Polx totally overconfident and that’s how the FDA blindsided. Aim is very illiquid and a poorly worded NHS toppled the price. That’s it ..
Xenon is already used in the market as a neuroprotectant. Plus the comment letter specifically doesn’t comment on safety and efficacy. So it won’t be the safety of the gas or it’s effectiveness. Usually that kind of comment is around manufacturing scale up capability, which is easily remedied. I doubt anything so severe as what Osirium suggests would be the comment list. It will truly be a few weeks to respond and then back on the horse.
It has been 4 years plus on safety and efficacy, which has had a positive read out. The company just failed to answer manufacturing questions. I’m sure it’s literally just some oversight somewhere because Polx got too confident. Makes total sense to me. FDA are unpredictable sometimes - this is drug / device manufacturing on hatch Waxman pathway - it’s pretty niche and full of technicalities
MTFB wasn’t even the same FDA pathway. MTFB was an antibiotic therapeutic that failed on efficacy. Polx is a drug device product that has manufacturing comments to amend. The efficacy and safety had a positive read out. You’re not being miserable, no, you’re being incorrect.
If the company supports with explanation and reassured market then we shouldn’t see dead cat. The market is trading on panic and lack of information- not typical. FDA usually has better negotiations than this - and this sort of thing is swept under the carpet. Polx just got confident and we’re utterly thrown under the bus. I think today is based on poor communication not fundamentals
Agree it’s FDA being extremely difficult on a technicality. Bracco imaging already has a 25% holding. Company only has a few hundred m market cap - easy Acq target. Even easier at 50% down - but I think Bracco has dibs. Bracco revenue is something like $18 billion - so I reckon they can afford it. I think it’ll get thru these FDA comments (ouch!) and crack on to commercialise. This technology helps kids with lung disease early diagnosis which makes a material difference to their lives. We need the tech after covid!